Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more
Aminologics Co.Ltd (074430) - Total Liabilities
Latest total liabilities as of September 2025: ₩26.95 Billion KRW
Based on the latest financial reports, Aminologics Co.Ltd (074430) has total liabilities worth ₩26.95 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aminologics Co.Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Aminologics Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aminologics Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Aminologics Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Calitech Co Ltd
TWO:6532
|
Taiwan | NT$271.10 Million |
|
Reliance Industrial Infrastructure Limited
NSE:RIIL
|
India | ₹662.20 Million |
|
GHCL TEXTILES LTD
NSE:GHCLTEXTIL
|
India | ₹2.47 Billion |
|
We & Win Development Co Ltd
TW:2537
|
Taiwan | NT$14.18 Billion |
|
Amoeba SA
PA:ALMIB
|
France | €20.64 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Aminologics Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aminologics Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aminologics Co.Ltd (2008–2024)
The table below shows the annual total liabilities of Aminologics Co.Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩5.09 Billion | +56.39% |
| 2023-12-31 | ₩3.26 Billion | -22.04% |
| 2022-12-31 | ₩4.18 Billion | -28.57% |
| 2021-12-31 | ₩5.85 Billion | -10.98% |
| 2020-12-31 | ₩6.57 Billion | +10.95% |
| 2019-12-31 | ₩5.92 Billion | +61.32% |
| 2018-12-31 | ₩3.67 Billion | -13.19% |
| 2017-12-31 | ₩4.23 Billion | -5.56% |
| 2016-12-31 | ₩4.48 Billion | -33.68% |
| 2015-12-31 | ₩6.75 Billion | -0.47% |
| 2014-12-31 | ₩6.78 Billion | -12.81% |
| 2013-12-31 | ₩7.78 Billion | -63.30% |
| 2012-12-31 | ₩21.20 Billion | -7.42% |
| 2011-12-31 | ₩22.90 Billion | -3.59% |
| 2010-12-31 | ₩23.75 Billion | +72.46% |
| 2008-12-31 | ₩13.77 Billion | -- |